Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peptide immunotherapy for allergic disease.

Michael Tarzi1, Mark Larché

  • 1Allergy and Clinical Immunology, Faculty of Medicine, Imperial College London, National Heart and Lung Institute, Dovehouse Street, London, SW3 6LY, UK. m.tarzi@ic.ac.uk

Expert Opinion on Biological Therapy
|July 2, 2003
PubMed
Summary

Specific immunotherapy for IgE-mediated diseases can cause reactions. Removing IgE-binding epitopes from allergens may improve safety. T cell epitopes are being explored for safer, effective allergy treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ACLY inhibition promotes tumour immunity and suppresses liver cancer.

Nature·2025
Same author

Mapping the intersection of demographics, behavior, and government response to the COVID-19 pandemic: an observational cohort study.

BMC global and public health·2025
Same author

Thermostabilization of a model viral-vectored oral thin film vaccine.

International journal of pharmaceutics·2025
Same author

Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.

Allergy·2023
Same author

Proceedings of the immune thrombocytopenia summit: new concepts in mechanisms, diagnosis, and management.

Research and practice in thrombosis and haemostasis·2023
Same author

Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.

Allergy·2022

Area of Science:

  • Immunology
  • Allergy Research
  • Vaccine Development

Background:

  • Specific immunotherapy is the only disease-modifying treatment for IgE-mediated diseases.
  • Current treatments carry a risk of systemic reactions due to intact allergen B cell epitopes.
  • T cells play a crucial role in allergic disease pathogenesis.

Purpose of the Study:

  • To explore the therapeutic potential of allergen-derived peptides for improved immunotherapy.
  • To investigate methods for enhancing the safety of specific immunotherapy by removing IgE-binding epitopes.
  • To address challenges in designing peptide-based vaccines due to human leukocyte antigen (HLA) polymorphism.

Main Methods:

  • Analysis of B cell and T cell epitopes within allergens.
  • Development of short, allergen-derived peptides to avoid IgE crosslinking.

Related Experiment Videos

  • Investigating major histocompatibility complex (MHC)-peptide-T cell receptor interactions.
  • Advancing epitope selection strategies.

    • Main Results:

    • Short peptides lack conformational determinants for IgE crosslinking, suggesting improved safety.
    • Understanding of epitope selection and MHC-peptide interactions has progressed.
    • Therapeutic strategies involving allergen-derived peptides have advanced to early clinical trials.

    Conclusions:

    • Allergen-derived peptides represent a promising therapeutic approach for IgE-mediated diseases.
    • Modifying immunotherapy to target T cell epitopes could enhance safety and maintain efficacy.
    • Ongoing research and clinical trials are validating peptide-based vaccine strategies for allergy treatment.